DelveInsight’s “Prurigo Nodularis Pipeline Insight” report provides comprehensive insights about key companies and pipeline drugs in the Prurigo Nodularis pipeline landscapes.
The report comprises Prurigo Nodularis pipelinedrug profiles, including clinical and non-clinical stage products. It also includes the Prurigo Nodularis therapeutics assessment by product type, stage, route of administration, and molecule type and further highlights the inactive Prurigo Nodularis pipeline products.
Prurigo Nodularis Overview
Prurigo nodularis is an intensely pruritic, chronic skin condition characterized by localized or generalized hyperkeratotic papules and nodules typically in a symmetrical distribution. Prurigo nodularis is accompanied by long-standing pruritus and is thought to develop as a reaction to repeated scratching in patients with Chronic Prurigo from various etiologies, including dermatological, systemic, infectious, and psychiatric.
Some of the key takeaways from the Prurigo Nodularis Pipeline Report:
-
Companies across the globe are diligently working toward the development of novel treatment therapies with a considerable amount of success over the years. Key players, such as Menlo Therapeutics, Trevi Therapeutics, Galderma, Dupixent, Amagen, Kiniksa Pharmaceuticals, Maruho, etc., are developing therapies for the treatment of Prurigo Nodularis.
-
Emerging therapies such as Serlopitant, Nalbuphine ER, Nemolizumab, Sanofi/ Regeneron, Apremilast, KPL-716, M118103, are expected to have a significant impact on the Prurigo Nodularis market in the coming years.
Get an overview of pipeline landscape @ Prurigo Nodularis Clinical Trials Analysis
Prurigo Nodularis Pipeline Therapies along with Key Players:
-
Serlopitant :Menlo Therapeutics
-
Nalbuphine ER: Trevi Therapeutics
-
Nemolizumab: Galderma
-
Sanofi/ Regeneron:Dupixent
-
Apremilast: Amagen
-
KPL-716:Kiniksa Pharmaceuticals
-
M118103:Maruho
Scope of Prurigo Nodularis Pipeline Drug Insight
-
Coverage: Global
-
Major Players: Menlo Therapeutics, Trevi Therapeutics, Galderma, Dupixent, Amagen, Kiniksa Pharmaceuticals, Maruho, and others.
-
Pipeline Therapies: Serlopitant, Nalbuphine ER, Nemolizumab, Sanofi/ Regeneron, Apremilast, KPL-716, M118103, and others.
Table of Contents
|
1 |
Prurigo Nodularis Report Introduction |
|
2 |
Prurigo Nodularis Executive Summary |
|
3 |
Prurigo Nodularis Overview |
|
4 |
Prurigo Nodularis-Analytical Perspective In-depth Commercial Assessment |
|
5 |
Prurigo Nodularis Pipeline Therapeutics |
|
6 |
Prurigo Nodularis Late Stage Products (Phase II/III) |
|
7 |
Prurigo Nodularis Mid Stage Products (Phase II) |
|
8 |
Prurigo Nodularis Early Stage Products (Phase I) |
|
9 |
Prurigo Nodularis Preclinical Stage Products |
|
10 |
Prurigo Nodularis Therapeutics Assessment |
|
11 |
Prurigo Nodularis Inactive Products |
|
12 |
Company-University Collaborations (Licensing/Partnering) Analysis |
|
13 |
Prurigo Nodularis Key Companies |
|
14 |
Prurigo Nodularis Key Products |
|
15 |
Prurigo Nodularis Unmet Needs |
|
16 |
Prurigo Nodularis Market Drivers and Barriers |
|
17 |
Prurigo Nodularis Future Perspectives and Conclusion |
|
18 |
Prurigo Nodularis Analyst Views |
|
19 |
Appendix |
|
20 |
About DelveInsight |
Related Reports:
DelveInsight’s ‘Prurigo Nodularis-Market Insights, Epidemiology, and Market Forecast—2030’ report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom),
Prurigo Nodularis Epidemiology
DelveInsight’s ‘Prurigo Nodularis Epidemiology Forecast to 2030′ report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/